Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.

Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, Kerr G, Yu K, Liang J, Cao Y, Chen Y, Lawrence MS, Langenbucher A, Gainor JF, Friboulet L, Dagogo-Jack I, Myers DT, Labrot E, Ruddy D, Parks M, Lee D, DiCecca RH, Moody S, Hao H, Mohseni M, LaMarche M, Williams J, Hoffmaster K, Caponigro G, Shaw AT, Hata AN, Benes CH, Li F, Engelman JA.

Nat Med. 2018 May;24(4):512-517. doi: 10.1038/nm.4497. Epub 2018 Mar 5.

PMID:
29505033
2.

Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.

Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N.

Cancer Discov. 2018 May;8(5):648-661. doi: 10.1158/2159-8290.CD-17-1452. Epub 2018 Feb 26.

PMID:
29483135
3.

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.

Shao W, Mishina YM, Feng Y, Caponigro G, Cooke VG, Rivera S, Wang Y, Shen F, Korn JM, Mathews Griner LA, Nishiguchi G, Rico A, Tellew J, Haling JR, Aversa R, Polyakov V, Zang R, Hekmat-Nejad M, Amiri P, Singh M, Keen N, Dillon MP, Lees E, Ramurthy S, Sellers WR, Stuart DD.

Cancer Res. 2018 Mar 15;78(6):1537-1548. doi: 10.1158/0008-5472.CAN-17-2033. Epub 2018 Jan 17.

PMID:
29343524
4.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

5.

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.

Germa C, Miller M, Mukhopadhyay P, Hewes B, Caponigro G, Scherer SJ, Hirawat S.

Ann Oncol. 2017 Aug 1;28(8):2021-2024. doi: 10.1093/annonc/mdx226. No abstract available.

6.

BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.

Emery CM, Monaco KA, Wang P, Balak M, Freeman A, Meltzer J, Delach SM, Rakiec D, Ruddy DA, Korn JM, Haling J, Acker MG, Caponigro G.

Mol Cancer Res. 2017 Oct;15(10):1431-1444. doi: 10.1158/1541-7786.MCR-17-0211. Epub 2017 Jun 27.

PMID:
28655712
7.

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart DD, Moutouh-de Parseval L, Demuth T, Dummer R.

Clin Cancer Res. 2017 Sep 15;23(18):5339-5348. doi: 10.1158/1078-0432.CCR-16-2923. Epub 2017 Jun 13.

8.

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.

Wood AC, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, Hart LS, King FJ, Smith TR, Ainscow E, Grandinetti KB, Tuntland T, Kim S, Caponigro G, He YQ, Krupa S, Li N, Harris JL, Mossé YP.

Clin Cancer Res. 2017 Jun 1;23(11):2856-2868. doi: 10.1158/1078-0432.CCR-16-1114. Epub 2016 Dec 16.

9.

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.

Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, Krupa S, Boehm M, Peters M, Caponigro G, Maris JM.

Clin Cancer Res. 2017 Apr 1;23(7):1785-1796. doi: 10.1158/1078-0432.CCR-16-1131. Epub 2016 Oct 11.

10.

High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.

Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, Farsidjani A, Zubrowski M, Sellers WR, Schlegel R, Porter D, Morris E, Wuerthner J, Jeay S, Greshock J, Halilovic E, Garraway LA, Caponigro G, Lehár J.

Cancer Res. 2016 Dec 1;76(23):6950-6963. Epub 2016 Sep 22.

11.

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M.

Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16.

12.

Early percutaneous endoscopic gastrostomy and nutritional supplementation for patients with head and neck cancer: an Italian survey of head and neck radiation oncologists.

Trignani M, Di Pilla A, Taraborrelli M, Perrotti F, Caponigro G, Santarelli G, Campitelli G, Croce A, De Nicola M, Genovesi D.

Support Care Cancer. 2015 Dec;23(12):3539-43. doi: 10.1007/s00520-015-2729-2. Epub 2015 Apr 9.

PMID:
25855041
13.

Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.

Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, Bhang HE, Taylor JE, Hu M, Englund NP, Yan F, Wang Z, Robert McDonald E 3rd, Wei L, Ma J, Easton J, Yu Z, deBeaumount R, Gibaja V, Venkatesan K, Schlegel R, Sellers WR, Keen N, Liu J, Caponigro G, Barretina J, Cooke VG, Mullighan C, Carr SA, Downing JR, Garraway LA, Stegmeier F.

Nat Genet. 2013 Nov;45(11):1386-91. doi: 10.1038/ng.2777. Epub 2013 Sep 29.

14.

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC, Pawel B, Cole KA, Maris JM.

Clin Cancer Res. 2013 Nov 15;19(22):6173-82. doi: 10.1158/1078-0432.CCR-13-1675. Epub 2013 Sep 17.

15.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA.

Nature. 2012 Mar 28;483(7391):603-7. doi: 10.1038/nature11003. Erratum in: Nature. 2012 Dec 13;492(7428):290.

16.

Advances in the preclinical testing of cancer therapeutic hypotheses.

Caponigro G, Sellers WR.

Nat Rev Drug Discov. 2011 Mar;10(3):179-87. doi: 10.1038/nrd3385. Review.

PMID:
21358737
17.

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA.

Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24.

18.

Single-vector inducible lentiviral RNAi system for oncology target validation.

Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, Chen Y, Caponigro G, Yao YM, Lengauer C, Sellers WR, Benson JD.

Cell Cycle. 2009 Feb 1;8(3):498-504. Epub 2009 Feb 25.

PMID:
19177017
19.

Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death.

Elis W, Triantafellow E, Wolters NM, Sian KR, Caponigro G, Borawski J, Gaither LA, Murphy LO, Finan PM, Mackeigan JP.

Mol Cancer Res. 2008 Apr;6(4):614-23. doi: 10.1158/1541-7786.MCR-07-0262.

20.

Functional analysis of expressed peptides that bind yeast STE proteins.

Caponigro G, Abedi M, Kamb A.

J Biotechnol. 2003 Aug 15;103(3):213-25.

PMID:
12890608
21.

A genetic selection method for expression products that induce apoptosis in adherent mammalian cell lines.

Sandrock R, Wheatley W, Drees E, Lualhati M, Kamb A, Caponigro G.

Apoptosis. 2003 Mar;8(2):209-19.

PMID:
12766481
22.

Expression levels of transdominant peptides and proteins in Saccharomyces cerevisiae.

Sandrock T, Poritz M, Kim M, Feldhaus MJ, Roth B, Caponigro G, Kamb A.

Yeast. 2002 Jan 15;19(1):1-7.

23.

Enrichment during transdominant genetic experiments using a flow sorter.

Sandrock R, Karpilow J, Richards B, Maxfield A, Wang C, Risley R, Rebentisch M, Drees B, Teng DH, Caponigro G, Kamb A.

Cytometry. 2001 Oct 1;45(2):87-95.

PMID:
11590620
24.

Transcriptional transactivation by selected short random peptides attached to lexA-GFP fusion proteins.

Abedi M, Caponigro G, Shen J, Hansen S, Sandrock T, Kamb A.

BMC Mol Biol. 2001;2:10. Epub 2001 Aug 31.

25.

Template selection during manipulation of complex mixtures by PCR.

Teng DH, Hsu F, Peterson I, Cardon KE, Caponigro G, Kamb A.

Biotechniques. 2001 Apr;30(4):868-72, 874, 876-7.

PMID:
11314269
26.

Peptide inhibitors expressed in vivo.

Kamb A, Caponigro G.

Curr Opin Chem Biol. 2001 Feb;5(1):74-7. Review.

PMID:
11166652
27.

Transdominant genetic analysis of a growth control pathway.

Caponigro G, Abedi MR, Hurlburt AP, Maxfield A, Judd W, Kamb A.

Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7508-13.

28.

Green fluorescent protein as a scaffold for intracellular presentation of peptides.

Abedi MR, Caponigro G, Kamb A.

Nucleic Acids Res. 1998 Jan 15;26(2):623-30.

29.

mRNA turnover in yeast promoted by the MATalpha1 instability element.

Caponigro G, Parker R.

Nucleic Acids Res. 1996 Nov 1;24(21):4304-12.

30.

An essential component of the decapping enzyme required for normal rates of mRNA turnover.

Beelman CA, Stevens A, Caponigro G, LaGrandeur TE, Hatfield L, Fortner DM, Parker R.

Nature. 1996 Aug 15;382(6592):642-6.

PMID:
8757137
31.

Mechanisms and control of mRNA turnover in Saccharomyces cerevisiae.

Caponigro G, Parker R.

Microbiol Rev. 1996 Mar;60(1):233-49. Review. No abstract available.

32.

Supplemental Content

Loading ...
Support Center